secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seer, Inc. (SEER)
CIK:        0001726445
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001628280-23-037369
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seer Q3 revenue $4.2M (+5% YoY), net loss $21.1M; guides to lower half of FY range
--------------------------------------------------------------------------------

- Revenue $4.2M (+5% YoY); product revenue $3.3M incl $1.4M related party; service $536K; grant $348K.
- Net loss $21.1M vs $24.0M YoY; operating expenses $28.0M with $8.3M stock-based compensation.
- Cash and investments $380.8M at Sep 30, 2023.
- FY 2023 revenue guided to lower half of $16-18M range due to ongoing macroeconomic headwinds.
- Expanded geographically with Danyel Biotech (Israel) and GeneTiCA (Eastern Europe); added Panome Bio as Center of Excellence.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1726445/000162828023037369/0001628280-23-037369-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1726445/000162828023037369/seer-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-037369

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer